

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

213051Orig1s000

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: September 17, 2019

TO: Administrative file for NDA 213051

FROM: Peter Franks, Regulatory Health Project Manager
Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II

SUBJECT: Officer/Employee List for NDA 213051

APPLICATION/DRUG: NDA 213051/Rybelsus (semaglutide) tablets

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Absar, Mohammad	Qiang, Yandong
Abugov, Robert	Ramaswamy, Muthukumar
Ayalew, Kassa	Rauschecker, Mitra
Basso, Federica	Sista, Sury
Braithwaite, Elena	Tran, Suong T
Bryant, Samantha	Wackes, Frank
Cao, Christian	Wang, Yun (FDA)
Chung, Amy	Williams, Marcia Britt
Conrad, Ariane	
Dinatale, Miriam	
Earp, Justin C	
Griffiths, LaShawn	
Khurana, Manoj	
Li, Vincent	
Liedtka, Jane	
Lin, Karl K	
Lu, Min	
Lungu, Andreea	
Manangeeswaran, Mohanraj	
Mandula, Haritha	
Mehta, Hina	
Nguyen, Maria	
Niak, Ali	
Penzenstadler, Justin	